Skip to main content

(RE)MIELINIZACION EN ESCLEROSIS MULTIPLE Y LEUCODISTROFIAS DESMIELINIZANTES RARAS: DESARROLLO DE MODELOS DE ENFERMEDAD IN VITRO E IN VIVO PARA CONSEGUIR PRODUCIR MIELINA

PID2022-143110OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Isolation of Oligodendrocyte Precursor Cells with Immunomagnetic Beads for Their Better Viability In Vitro and In Vivo.

  • Gómez-Martín, Paula
  • Macías-Castellano, Alba
  • Fernández-Gómez, Beatriz
  • Sánchez-Jiménez, Estefanía
  • Marchena, Miguel
  • Castro Soubriet, Fernando de
Oligodendrocytes (OLs) are glial cells that myelinate axons in the central nervous system (CNS). These cells are generated from oligodendrocyte precursor cells (OPCs) during CNS development, and the population of OPCs that remain in the adult is responsible for spontaneous remyelination in demyelinating diseases such as multiple sclerosis (MS). Thus, OPCs represent an interesting source for regenerative therapies. Here, we describe an updated protocol for isolation of OPCs based on the magnetic cell separation (MACS) technology and oligodendroglial lineage-specific markers. After the extraction of nerve tissue, mechanical and enzymatic dissociation is performed. The cells are then immunomagnetically labeled and separated through columns composed of a matrix of ferromagnetic spheres coupled to the magnetic field of the MACS separator. This method has several advantages: it is significantly more efficient and faster if compared to other conventional methods, such as flow cytometry or shaking. In addition, the OPCs isolated in this way are significantly more viable, which facilitates their use of these cells in different experimental approaches, both in vitro and in vivo., FdC and his research group are currently supported by the following Spanish institutions: Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (grant PID2022-143110OB-100— funded by MCIN/AEI/10.13039/501100011033 FEDER/EU-), Fundación Ramón Areces (grant CIVP19A5917), Fundación Merck Salud (Ayudas Merck de Investigación 2023), Fundación GAEM (contract # 050601240006), Asociación Europea contra la leucodistrofia-ELA España and Fundación Hesperia (contract # 050601240019) all to FdC. The research group is also part of research networks #RED2022-134081-T and # RED2022-134425-T, both financed by the Spanish Agencia Estatal de Investigación. PG-M was contracted as Ayudante de Investigación (PEJ-2020-AI/BMD-18541, associated with the Fondo de Garantía Juvenil, Comunidad de Madrid, Spain, to FdC) and now hired under grant PID2022-143110OB-100. BF-G was hired under IND2018/BMD-9751 (Programa de Doctorados Industriales, Comunidad de Madrid) to FdC, and she is currently hired by AptaTargets, SL. AM-C is currently hired under Fundación Merck Salud (Ayudas Merck de Investigación 2023). We are deeply indebted to Dr. Ana Bribián (Sanofi, Spain) and Dr. Carolina Melero-Jerez (JazzPharma, Spain), previous members of our research group, for their fundamental contributions that paved the path to reach the present protocol.